Hyponatremia is a frequent complication following pituitary surgery. We report a case with hyponatremia after surgery of a pituitary adenoma that was successfully treated with tolvaptan. A 68-year-old man with a pituitary tumor presented with mild hyponatremia (133 mEq/L) before surgery. The patient developed hyponatremia (125 mEq) 4 days postsurgery, and 10% sodium chloride was infused. Seven 7 days postsurgery, hyponatremia was improved (132 mEq/L), and tolvaptan 15 mg was given orally as a single dose instead of the 10% sodium chloride infusion. His serum sodium remained within normal limits. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) after pituitary surgery most probably led to the hyponatremia, and tolvaptan was effective because it is an oral vasopressin receptor antagonist.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648721 | PMC |
| http://dx.doi.org/10.1055/s-0035-1564605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of low-dose tolvaptan (7.5mg) in the treatment of inpatient hyponatraemia: a retrospective study.
Endocr Pract
December 2024
Department of Endocrinology, King's College Hospital NHS Foundation Trust, London, United Kingdom. Electronic address:
Objectives: The recommended dose of tolvaptan for hyponatraemia secondary to SIADH is 15mg. We evaluated the efficacy of an initial 7.5mg dose and determined the frequency where sodium (Na+) correction exceeded safe limits, defined as an increment of ≥10 mmol/L, within the initial 8 or 24 hours of administration.
View Article and Find Full Text PDFComparative study of the effectiveness of tolvaptan versus urea in patients with hyponatremia caused by SIADH.
Rev Clin Esp (Barc)
December 2024
Unidad de Medicina Oral, Cirugía Oral e Implantología, Facultad de Medicina y Odontología, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
Background And Objectives: Hyponatraemia is common in elderly and hospitalised patients, often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). This study evaluates the efficacy and safety of tolvaptan and urea in patients with hyponatraemia and SIADH.
Materials And Methods: An observational cohort study was conducted on 198 patients with SIADH and hyponatraemia (Na+ <135 mmol/L) at the Complejo Hospitalario Universitario de Pontevedra from January 2015 to May 2022.
Delayed Emergence of Isolated Secondary Adrenal Insufficiency: A Case Report.
Cureus
October 2024
Family Medicine, Baptist Health of South Florida, Miami, USA.
Article Synopsis
- Secondary adrenal insufficiency (SAI) is a rare condition caused by a deficiency in the adrenocorticotropic hormone (ACTH) from the pituitary gland, leading to symptoms like chronic low sodium levels (hyponatremia), and can present a diagnostic challenge, particularly when there are no identifiable triggers.
- An 80-year-old woman with a history of multiple health issues was diagnosed with isolated adrenal insufficiency after presenting with weakness and fatigue, leading to complications that required specific treatments including corticosteroids.
- This case highlights the importance of recognizing atypical presentations of adrenal insufficiency, as well as the effectiveness of corticosteroid replacement therapy in resolving symptoms and normalizing sodium levels.
Duloxetine-Induced Antidiuresis in Rats with Lithium-Induced Nephrogenic Diabetes Insipidus.
Life (Basel)
August 2024
Biomedical Research Institute, Hanyang University College of Medicine, 222-1 Wansimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea.
Antidepressants, including duloxetine, are a significant cause of drug-induced hyponatremia, which can disrupt the continuation of medication. Tolvaptan is beneficial for correcting hyponatremia caused by the syndrome of inappropriate antidiuresis, but its impact on duloxetine-induced hyponatremia remains unknown. We used male Sprague-Dawley rats to examine the impact of duloxetine treatment on lithium-induced nephrogenic diabetes insipidus (Li-NDI) and to evaluate whether the results were reversed by co-treatment with tolvaptan.
View Article and Find Full Text PDFThe Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer.
Int J Mol Sci
August 2024
Pituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy.
Article Synopsis
- The AVPR2 antagonist tolvaptan was shown to reduce tumor growth and increase apoptosis in small cell lung cancer using a mouse model.
- Mice treated with tolvaptan had significantly smaller tumors and better signs of survival compared to the control group.
- The treatment inhibited key signaling pathways associated with cancer progression and decreased markers linked to cell proliferation while increasing those associated with cell death.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!